FILING ANALYSIS · TUESDAY, OCTOBER 13
IMMUCELL CORP /DE/ ICCC — 8-K: Results of Operations and Financial Condition
positive
ImmuCell reports a 46% increase in product sales for Q3 2026, driven by a recovery from depressed sales levels in Q3 2025 and improvements in commercial execution, with total sales reaching $8.0 million.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →